Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x

CSPC Aktie

 >CSPC Aktienkurs 
1.112 EUR    +3.5%    (TradegateBSX)
Ask: 1.109 EUR / 5409 Stück
Bid: 1.075 EUR / 5584 Stück
Tagesumsatz: 5 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
CSPC Aktie über LYNX handeln
>CSPC Performance
1 Woche: +8,4%
1 Monat: +2,0%
3 Monate: +25,1%
6 Monate: -6,2%
1 Jahr: +92,3%
laufendes Jahr: +19,6%
>CSPC Aktie
Name:  CSPC PHARMACEUTICAL GROUP
Land:  Hong Kong (China)
Sektor:  Gesundheit
ISIN/ Wkn:  HK1093012172 / 548183
Symbol/ Ticker:  CVG (Frankfurt)
Kürzel:  FRA:CVG, ETR:CVG, CVG:GR
Index:  -
Webseite:  https://www.cspc.com.hk/
Profil:  CSPC Pharmaceutical Group Ltd. is a prominent player in the pharmaceutical industry, focusing on the research, development, manufacture, and commercialization of a wide array of pharmaceutical product..
>Volltext..
Marktkapitalisierung:  12568.75 Mio. EUR
Unternehmenswert:  11669.25 Mio. EUR
Umsatz:  3011.01 Mio. EUR
EBITDA:  651.13 Mio. EUR
Nettogewinn:  445.86 Mio. EUR
Gewinn je Aktie:  0.04 EUR
Schulden:  58.19 Mio. EUR
Liquide Mittel:  889.96 Mio. EUR
Operativer Cashflow:  755.8 Mio. EUR
Bargeldquote:  0.96
Umsatzwachstum:  -25.9%
Gewinnwachstum:  -41.39%
Dividende je Aktie:  0.03 EUR
Dividendenrendite:  2.37%
Dividendenschätzung:  2.37%
Div. Historie:  17.10.25 - 0.0154616€
04.06.25 - 0.011044€
>weitere anzeigen...
Insiderhandel:  -
Suchwörter:  CSPC
Letzte Datenerhebung:  16.02.26
>CSPC Kennzahlen
Aktien/ Unternehmen:
Aktien: 11522.5 Mio. St.
Frei handelbar: 67.75%
Leerverk. Aktien: -
Rückkaufquote: 1.48%
Mitarbeiter: 21400
Umsatz/Mitarb.: 0.16 Mio. EUR
Analysten:
Analystenrating: Buy
Kursziel: 16.3%
Bewertung:
KGV: 27.55
KGV lG: 20.49
KUV: 4.05
KBV: 3.15
PEG-Ratio: -
EV/EBITDA: 17.92
Rentabilität:
Bruttomarge: 66.76%
Gewinnmarge: 14.81%
Operative Marge: 16.25%
Managementeffizenz:
Gesamtkaprendite: 8.16%
Eigenkaprendite: 11.25%
>CSPC Peer Group
Gesundheit, Medizin für Bakterielle- & Pilzinfektionen/ Antibiotika, Nahrungsergänzungsmittel & Wellnessprodukte, Onkologie/ Krebs- Behandlung
 
16.02.26 - 04:45
Research: Nomura Lifts CSPC PHARMA (01093.HK) TP to $12.04, Keeps Buy Rating (AAStocks)
 
Nomura issued a research report expecting that CSPC PHARMA (01093.HK)'s 4Q25 revenue will grow by 20% YoY to RMB7.6 billion, slightly higher than the market consensus of RMB7.4 billion. The broker also anticipated that the sales of finished drugs will ebb by 1% YoY to RMB5 billion, while collaboration revenue will be RMB1.1 ......
10.02.26 - 09:15
Full-day Takeaway: HSI Closes at 27,183, Up 155 pts; HSTI Closes at 5,451, Up 33 pts; CSPC PHARMA Up over 5%; ZTO EXPRESS-W, WH GROUP, BOC HONG KONG, WHARF REIC, HANG LUNG PPT Hit New Highs; Market Turnover Rises (AAStocks)
 
At close, HSI rose 155 pts or 0.6% to 27,183. HSTI rose 33 pts or 0.6% to 5,451. HSCEI gained 74 pts or 0.8% to 9,242. Market turnover reached $234.04 billion.Active Heavyweights:MEITUAN (03690.HK) closed at $88.8, down 2.5%BABA (09988.HK) closed at $160.5, up 1.6%TENCENT (00700.HK) closed at $551, down 1.6%XIAOMI (01810.HK) clo......
03.02.26 - 09:15
Full-day Takeaway: HSI Closes at 26,834, Up 59 pts; HSTI Closes at 5,467, Down 59 pts; CSPC PHARMA Up over 8%; NEW ORIENTAL, HSBC HOLDINGS, MTR CORPORATION, POWER ASSETS, CIMC Hit New Highs; Market Turnover Rises (AAStocks)
 
At close, HSI rose 59 pts or 0.2% to 26,834. HSTI dropped 59 pts or 1.1% to 5,467. HSCEI fell 27 pts or 0.3% to 9,053. Market turnover reached $335.15 billion.Active Heavyweights:TENCENT (00700.HK) closed at $581, down 2.9%MEITUAN (03690.HK) closed at $93.2, down 1.7%BABA (09988.HK) closed at $161, down 1.4%XIAOMI (01810.HK) clo......
02.02.26 - 18:15
AZN Obesity Pipeline to Get a Boost From Deal With China′s CSPC (Zacks)
 
AstraZeneca deepens its obesity push with an eight-program deal with China's CSPC, securing rights to a once-monthly injectable weight-management pipeline....
02.02.26 - 06:00
Research: CICC Raises CSPC PHARMA (01093.HK) TP to $12, Anticipates Continued Out-licensing Realization (AAStocks)
 
CSPC PHARMA (01093.HK) and its subsidiaries authorized AstraZeneca to exclusively develop, produce and commercialize eight innovative long-acting peptide medicine projects globally, excluding mainland China and Hong Kong, Macau, and Taiwan, according to CICC's research report. This includes SYH2082 and three preclinical stag......
02.02.26 - 04:15
Research: BofAS Adds CSPC PHARMA (01093.HK) TP to $9.1, Keeps Underperform Rating on Sales Pressure (AAStocks)
 
CSPC PHARMA (01093.HK) reached an agreement with AstraZeneca to develop innovative long-acting peptide medicines, with the total value of the agreement potentially reaching up to US$18.5 billion, according to a research report issued by BofA Securities. Pursuant to the agreement, CSPC PHARMA will receive an upfront payment of US......
31.01.26 - 12:12
AstraZeneca obesity tie-up with CSPC seen as shrewd move (Proactive Investors)
 
Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...
30.01.26 - 23:00
AstraZeneca strikes £13bn fat jabs deal with Chinese drug giant (DailyMail)
 
Under the deal, the FTSE 100 group will have the exclusive global rights, outside China, to CSPC's once-a-month jab that is about to start early-stage clinical trials....
30.01.26 - 12:12
AstraZeneca strikes collaborative agreement with CSPC Pharmaceuticals (ShareCast)
 
Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...
30.01.26 - 11:30
HKD934.6M Southbound Trading Net Inflow to CSPC PHARMA (AAStocks)
 
There was HKD934.6 million, HKD914 million and HKD329.8 million Southbound Trading net inflow to CSPC PHARMA (01093.HK), XIAOMI-W (01810.HK) and BABA-W (09988.HK).There was HKD635.5 million, HKD525.5 million and HKD213.4 million Southbound Trading net outflow from ZIJIN MINING (02899.HK), CNOOC (00883.HK) and TENCENT (00700.HK).......
30.01.26 - 11:18
AstraZeneca strikes obesity deal with China′s CSPC Pharmaceuticals (Alliance)
 
AstraZeneca PLC on Friday said it has expands its weight-management pipeline by collaborating with China's CSPC...
30.01.26 - 10:36
Abnehm-Boom: AstraZeneca sichert sich CSPC-Peptidrechte (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
30.01.26 - 09:42
Astrazeneca sichert sich Adipositas-Medikamenten-Rechte von Chinas CSPC (Dow Jones)
 
Von Adria Calatayud DOW JONES--Astrazeneca hat eine Kooperations- und Lizenzvereinbarung mit der chinesischen CSPC Pharmaceutical geschlossen, um sich die Rechte außerhalb ......
30.01.26 - 09:24
AstraZeneca strikes up to $18.5B obesity drug deal with China’s CSPC Pharmaceutical (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
30.01.26 - 09:18
AstraZeneca Strikes Deal With CSPC To Boost Obesity And Diabetes Therapies (AFX)
 
LONDON (dpa-AFX) - AstraZeneca PLC (AZN) said on Friday it has entered a strategic collaboration with CSPC Pharmaceuticals, paying $1.2 billion upfront to expand its weight-management pipeline. Th......
30.01.26 - 08:42
Astra Signs Obesity Deal With CSPC Worth Up to $18.5 Billion (Bloomberg)
 
AstraZeneca Plc agreed an obesity drug deal with Chinese company CSPC Pharmaceutical Group Ltd. worth up to $18.5 billion, as the British drugmaker tries to push into the growing weight-loss market....
30.01.26 - 08:00
AstraZeneca agrees obesity and T2D deal with CSPC (Cision)
 
30 January 2026 AstraZeneca enhances its weight management portfolio through collaboration agreement with CSPC Pharmaceuticals Agreement includes eight programmes, including a clinical-ready asset, plus access to advanced AI-driven peptide drug discovery platform and innovative monthly dosing technology   AstraZeneca strengthens its weight management portfolio through a new strategic collaboration agreement with CSPC Pharmaceuticals to advance the development of multiple next-generation therapies for obesity and type 2 diabetes across eight programmes. Under this agreement, the...
30.01.26 - 07:12
AstraZeneca zahlt CSPC Pharma bis zu 18,5 Milliarden Dollar für Adipositas-Medikamente (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
30.01.26 - 06:42
China′s CSPC Pharmaceutical, AstraZeneca partner on long-acting obesity drugs (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
30.01.26 - 06:00
H Shrs: HSI Dives 498 Pts at Midday; Commodity Stocks Plunge; CSPC PHARMA Dives 12%+ (AAStocks)
 
The market kept tabs on US President Donald Trump's announcement of the Fed Chair nominee, with the DXY rising. Hong Kong bourse sagged in the morning session. The HSI opened 182 points lower, and extended its decline, slumping 536 points at one point to bottom at 27,431, closing the morning session down 498 points or 1.8% a......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Auf Kontinuität setzen vor allem die, denen noch nie etwas Neues eingefallen ist. - Dr. Fritz P. Rinnhofer
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!